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August 11, 2009:661–8tudy that there were no renal hemodynamic differences between
iuretics and ultrafiltration.
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eply
e appreciate the enthusiastic interests and insightful comments
egarding our report on the potential role of venous congestion as
driver for worsening renal function (WRF) in patients admitted
ith advanced decompensated heart failure (ADHF) (1). We have
cknowledged in the report that many factors can contribute in the
athophysiology of WRF in the setting of ADHF. While our
xisting data cannot demonstrate direct causation between elevated
entral venous pressure and WRF, our current treatment goals are
o reduce filling pressures and to improve cardiac output using a
ide range of drug and device therapies according to protocols
stablished in our heart failure intensive care unit. It is important
o clarify that the mean dosages of furosemide during intensive
edical therapy were similar among patients who did and did not
evelop WRF, with similar percentages of patients in both groups
eceiving furosemide through continuous parental infusion. While
he biggest hemodynamic determinant of the subsequent develop-
ent of WRF in this patient population with initially depressed
ardiac index appeared to be elevated central venous pressure rather
han low cardiac output, we believe our data supported the
resence of venous congestion as the driver of the process, either
ue to underlying restrictive physiology, overzealous diuretic use,
eurohormonal up-regulation, or more likely the severity of
ongestion. Dissecting these factors may be challenging in the
linical setting, and may vary widely among individual patients.
egardless, this is a clear departure from the traditional “cardio-
entric” concept of impaired cardiac output as the primary deter-
inant of cardio-renal compromise in some patients with ADHF.
Contrary to animal experiments, we did not observe a direct
orrelation between baseline renal function and severity of venous
ongestion; several reasons might account for this discrepancy.
irst, the duration and onset of venous congestion in the quoted
nimal experiments always was acute and short-lived while in
atients admitted with ADHF venous congestion most often arises olowly and gradually over the preceding weeks. Second, some of
ur patients have been treated with long-term neurohormonal
ntagonists and may have pre-existing/intrinsic renal dysfunction
ontrary to animal models, which had normal renal function at the
oment venous pressure was artificially raised. Furthermore, other
xtrinsic factors as a result of long-term venous congestion (such as
aised intra-abdominal pressure caused by visceral edema or
scites) may contribute to this cardio-renal pathophysiology (2).
owever, the first step is to recognize that venous congestion is a
ajor feature of the syndrome, which is the primary message of
his and several other recent papers in different patient populations
3,4). We fully agree that more rigorous studies are needed, and we
elieve that the search for future ADHF therapies should focus on
trategies that allow safe and optimal reduction and prevention of
enous congestion to prevent such a devastating complication.
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e appreciate the opportunity to answer the thoughtful letter of
rs. Maqsood and Szerlip, who raised the issues of the role of
igorous diuresis in the patients discussed in the article by Mullens
t al. (1), and the activation of the renin-angiotensin-aldosterone
ystem (RAAS) after ultrafiltration (2).
Our interpretation of the study by Mullens et al. (1) is that the
entral venous pressure decrease in the worsening renal function
WRF) group was not significantly different from that of the
on-WRF group, approximately 35%. Nevertheless, the central
enous pressure remained significantly (p  0.04) higher in the
RF group. We think this supports the hypothesis proposed by
ullens et al. (1) about the important role of venous congestion in
ontributing to WRF.
Our suggestion about the differing activation of the RAAS with
iuretics and ultrafiltration is derived from an elegant study done
ver a decade ago. In 1994, Agostoni et al. (3) demonstrated that
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August 11, 2009:661–8n heart failure patients treated with either ultrafiltration or
iuretics to achieve equivalent fluid removal, sustained hemody-
amic and neurohormonal benefit occurred only in the ultrafiltra-
ion group. Compared with the diuretic group, patients treated
ith ultrafiltration had lower norepinephrine, plasma renin, and
ldosterone levels for up to 90 days. Lower RAAS activation was
ssociated with sustained improvement in objective measures of
unctional capacity. The rate of 14 to 15 ml/min for interstitial
uid mobilization was outlined still earlier by Fauchald and
auchald (4), as recently reviewed by Schrier (5).
The conclusions of Rogers et al. (6) about the impact of
iuretics and ultrafiltration on renal function might or might not
e verified in larger trials. However, we feel strongly that the
mportant outcomes in subsequent studies involving patients hos-
italized with heart failure remain focused on a reduction of
ardiovascular mortality and heart failure rehospitalizations, rather
han on the more specific end point of renal function. This is
here we propose that new tactics are needed.
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s it Myocarditis or
rrhythmogenic Right
entricular Cardiomyopathy?
ieroni et al. (1) conclude that right ventricular myocarditis
requently mimics arrhythmogenic right ventricular cardiomyopa-
hy (ARVC), and 3-dimensional electroanatomic mapping (guided
ndomyocardial biopsy is a tool that can differentiate the 2 entities,
uiding appropriate therapy. The gist of their message suggests chat these 2 entities are mutually exclusive, and in their cohort,
lectrocardiographic abnormalities, arrhythmias, right ventricular
tructural and functional abnormalities, Task Force criteria fulfill-
ent, a 3-dimensional voltage map, and inducible arrhythmias on
lectrophysiologic testing could not separate the wheat from the
haff. Some experts have suggested that a “hot phase” may
nterpolate periods of clinical quiescence, and the former may
resent as myocarditis or worsening ventricular arrhythmia (2). If
e were to acknowledge the possibility of this alternative hypoth-
sis, the findings may be interpreted differently. The 15 patients
ho were diagnosed with myocarditis may represent a hot phase,
nd although they did not have fibrofatty changes, they fulfilled
ask Force criteria, which are quite specific for the diagnosis of the
isease. These patients with myocarditis may represent an earlier
hase of the disease, and the observation that none of these
atients experienced arrhythmic events gives credence to this
ossibility. Genetic testing in this sample would have been highly
esirable even though it is not considered necessary for diagnosis
y the authors. We agree with the authors that a revision and
eappraisal of diagnostic criteria for ARVC is long overdue.
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yocarditis Mimicking
rrhythmogenic Right
entricular Cardiomyopathy
e have read with interest the paper by Pieroni et al. (1)
ddressing myocarditis as a common differential diagnosis to
rrhythmogenic right ventricular cardiomyopathy (ARVC).
mong 30 patients noninvasively fulfilling Task Force criteria (2)
or ARVC, they found that 15 patients actually had myocarditis
ased on 3-dimensional electroanatomic voltage mapping-guided
ndomyocardial biopsy. Voltage-guided biopsy is an elegant way of
btaining histological material from areas of the right ventricle
ith electrical signs of regional abnormalities and may facilitate the
iagnostic workup. However, we have the following questions/
oncerns about the study by Pieroni et al. (1):
